Patents by Inventor Hariharan Venkatesan

Hariharan Venkatesan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trifluoromethyl alcohols as modulators of ROR?t
    Patent number: 10150762
    Abstract: The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R1-1-carbonyl)thiazole-2-carboxamide, wherein R1 is defined in the specification.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 11, 2018
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20180215732
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: September 5, 2017
    Publication date: August 2, 2018
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20180148435
    Abstract: Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
    Type: Application
    Filed: February 17, 2017
    Publication date: May 31, 2018
    Inventors: Michael H. RABINOWITZ, Mark D. ROSEN, Kyle T. TARANTINO, Hariharan VENKATESAN
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20180022733
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: September 5, 2017
    Publication date: January 25, 2018
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Trifluoromethyl alcohols as modulators of ROR?t
    Patent number: 9850236
    Abstract: The present invention comprises compounds of Formula I. wherein: X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Amide substituted thiazoles as modulators of RORyt
    Patent number: 9845319
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R5, A1, A2, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 19, 2017
    Assignee: Janssen Pharmaceutiuca NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Maud Urbanski, Aihua Wang, David Kummer, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
    Publication number: 20170327492
    Abstract: The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R1-1-carbonyl)thiazole-2-carboxamide, wherein R1 is defined in the specification.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 16, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20170320859
    Abstract: Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
    Type: Application
    Filed: February 17, 2017
    Publication date: November 9, 2017
    Inventors: Michael H. RABINOWITZ, Mark D. ROSEN, Kyle T. TARANTINO, Hariharan VENKATESAN
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20170313691
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • ALKYL LINKED QUINOLINYL MODULATORS OF ROR?t
    Publication number: 20170258782
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 14, 2017
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • QUINOLINYL MODULATORS OF RORyt
    Publication number: 20170182056
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: March 2, 2017
    Publication date: June 29, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings, Kelly McClure, Virginia Tanis
  • Quinolinyl modulators of ROR?t
    Patent number: 9624225
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 18, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Xiaohua Xue, Maxwell D. Cummings, Kelly McClure, Virginia Tanis
  • 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
    Patent number: 9573940
    Abstract: Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: February 21, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan
  • PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat
    Publication number: 20160279122
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: June 14, 2016
    Publication date: September 29, 2016
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • Phenyl linked quinolinyl modulators of ROR?t
    Patent number: 9403816
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 2, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Maxwell D. Cummings
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20160168127
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 16, 2016
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Alkyl linked quinolinyl modulators of ROR?t
    Patent number: 9346782
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 24, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Maxwell D. Cummings
  • HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
    Publication number: 20160136149
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7 R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: January 22, 2016
    Publication date: May 19, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
    Publication number: 20160122336
    Abstract: The present invention comprises compounds of Formula I. wherein: X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyt
    Publication number: 20160122335
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R5, A1, A2, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Maud Urbanski, Aihua Wang, David Kummer, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann